Cargando…

Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis

INTRODUCTION: We compared treatment switch patterns and healthcare costs among biologic-naive patients with psoriatic arthritis (PsA) who initiated apremilast or biologics. METHODS: A 1:2 propensity score match was used to adjust administrative claims data for adults initiating apremilast or biologi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jashin J., Pelletier, Corey, Ung, Brian, Tian, Marc, Khilfeh, Ibrahim, Curtis, Jeffrey R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467475/ https://www.ncbi.nlm.nih.gov/pubmed/32141018 http://dx.doi.org/10.1007/s12325-020-01262-9

Ejemplares similares

Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis
por: Kaplan, David L, et al.
Publicado: (2020)

Biologic Initiation Rate in Systemic-Naïve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database
por: Husni, M Elaine, et al.
Publicado: (2022)

Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis
por: Zhang, Hanzhe, et al.
Publicado: (2021)

Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence
por: Costa, Luisa, et al.
Publicado: (2017)

Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
por: Palmer, Jacqueline B., et al.
Publicado: (2016)

Duration of psoriatic arthritis as a risk factor for myocardial infarction
por: Egeberg, Alexander, et al.
Publicado: (2018)

Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs
por: Zhang, Huabin F, et al.
Publicado: (2014)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
por: Bhushan, Vandana, et al.
Publicado: (2021)

Altered Bone Biology in Psoriatic Arthritis
por: Rahimi, Homaira, et al.
Publicado: (2012)

Healthcare Cost and Utilization Associated with Biologic Treatment Patterns Among Patients with Psoriatic Arthritis: Analyses from a Large US Claims Database
por: Hur, Peter, et al.
Publicado: (2020)

Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry
por: Mease, Philip J, et al.
Publicado: (2019)

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Real‐World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study
por: Murage, Mwangi J., et al.
Publicado: (2021)

Economic impact of biologic utilization patterns in patients with psoriatic arthritis
por: Schwartzman, Sergio, et al.
Publicado: (2017)

Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
por: Buchanan, Vanessa, et al.
Publicado: (2018)

Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic
por: Johnston, Stephen S., et al.
Publicado: (2015)

An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis
por: Chimenti, Maria Sole, et al.
Publicado: (2020)

Immunogenicity to biological drugs in psoriasis and psoriatic arthritis
por: Valenzuela, Fernando, et al.
Publicado: (2021)

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J, et al.
Publicado: (2018)

Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
por: Ebina, Kosuke, et al.
Publicado: (2020)

Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
por: Furer, Victoria, et al.
Publicado: (2023)

Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system – the case of Poland
por: Raciborski, Filip, et al.
Publicado: (2016)

Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis
por: Cannon, Grant W., et al.
Publicado: (2016)

Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
por: Sfikakis, Petros P., et al.
Publicado: (2023)

Quality of healthcare information on YouTube: psoriatic arthritis
por: Onder, Mustafa Erkut, et al.
Publicado: (2021)

Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
por: D’Angelo, Salvatore, et al.
Publicado: (2017)

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)
por: Nash, Peter, et al.
Publicado: (2018)

Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics
por: Silvy, Florent, et al.
Publicado: (2015)

Quo vadis, biological treatment for psoriasis and psoriatic arthritis?
por: Olszewska, Barbara, et al.
Publicado: (2018)

Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis
por: Thibodeaux, Quinn, et al.
Publicado: (2019)

Treatment persistence of biologics among patients with psoriatic arthritis
por: Haddad, Amir, et al.
Publicado: (2021)

Distinct In Vitro T-Helper 17 Differentiation Capacity of Peripheral Naive T Cells in Rheumatoid and Psoriatic Arthritis
por: Baricza, Eszter, et al.
Publicado: (2018)

Psoriatic arthritis
por: Sankowski, Artur Jacek, et al.
Publicado: (2013)

Psoriatic Arthritis
por: Fitzgerald, Kara, et al.
Publicado: (2012)

Psoriatic arthritis
por: Ocampo D, Vanessa, et al.
Publicado: (2019)

Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis
por: Song, Yan, et al.
Publicado: (2019)

Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate
por: Tkacz, Joseph, et al.
Publicado: (2020)

The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy
por: Olivieri, I., et al.
Publicado: (2008)

Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2
por: McInnes, Iain B, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_flp1phse39di2bprkor5eqfn7s